US7138486B2
(en)
*
|
1986-05-05 |
2006-11-21 |
The General Hospital Corporation |
Insulinotropic hormone derivatives and uses thereof
|
ATE357509T1
(de)
*
|
1997-09-29 |
2007-04-15 |
Point Therapeutics Inc |
Stimulierung von hämatopoietischen zellen im vitro
|
EP2433623A1
(en)
*
|
1998-02-02 |
2012-03-28 |
Trustees Of Tufts College |
Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
|
BR9913153A
(pt)
*
|
1998-08-21 |
2001-05-15 |
Point Therapeutics Inc |
Normalização da atividade do substrato
|
US6979697B1
(en)
|
1998-08-21 |
2005-12-27 |
Point Therapeutics, Inc. |
Regulation of substrate activity
|
CO5150173A1
(es)
*
|
1998-12-10 |
2002-04-29 |
Novartis Ag |
Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
|
US7745216B2
(en)
*
|
1999-02-10 |
2010-06-29 |
Curis, Inc. |
Methods and reagents for treating glucose metabolic disorders
|
US6548529B1
(en)
|
1999-04-05 |
2003-04-15 |
Bristol-Myers Squibb Company |
Heterocyclic containing biphenyl aP2 inhibitors and method
|
US6890904B1
(en)
*
|
1999-05-25 |
2005-05-10 |
Point Therapeutics, Inc. |
Anti-tumor agents
|
US6110949A
(en)
*
|
1999-06-24 |
2000-08-29 |
Novartis Ag |
N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
|
US6380398B2
(en)
|
2000-01-04 |
2002-04-30 |
Novo Nordisk A/S |
Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
|
PT1248604E
(pt)
*
|
2000-01-21 |
2007-01-31 |
Novartis Ag |
Associações compreendendo inibidor de dipeptidilpeptidase-iv
|
WO2001055105A1
(en)
*
|
2000-01-24 |
2001-08-02 |
Novo Nordisk A/S |
N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
|
WO2001062266A2
(en)
*
|
2000-02-25 |
2001-08-30 |
Novo Nordisk A/S |
Use of dpp-iv inhibitors for the treatment of diabetes
|
WO2001066135A1
(en)
*
|
2000-03-08 |
2001-09-13 |
Novo Nordisk A/S |
Lowering serum lipids
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
US6500804B2
(en)
|
2000-03-31 |
2002-12-31 |
Probiodrug Ag |
Method for the improvement of islet signaling in diabetes mellitus and for its prevention
|
AU2001268958B2
(en)
|
2000-07-04 |
2006-03-09 |
Novo Nordisk A/S |
Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
|
EP1970072A1
(en)
|
2000-09-18 |
2008-09-17 |
Sanos Bioscience A/S |
Use of GLP-2 peptides for the treatment of hyperparathyroidism
|
US7371721B2
(en)
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
EP1328270A2
(en)
*
|
2000-10-27 |
2003-07-23 |
Probiodrug AG |
Method for the treatment of neurological and neuropsychological disorders
|
EP1891948A1
(en)
|
2000-10-27 |
2008-02-27 |
Probiodrug AG |
Treatment of neurological and neuropsychological disorders
|
WO2002067918A1
(fr)
*
|
2001-02-27 |
2002-09-06 |
Banyu Pharmaceutical Co., Ltd. |
Nouveau derive de diallylmethylamine
|
DK1385856T3
(da)
|
2001-04-11 |
2006-05-15 |
Bristol Myers Squibb Co |
Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
|
AU2002322344C1
(en)
|
2001-06-27 |
2006-02-16 |
Smithkline Beecham Corporation |
Fluoropyrrolidines as dipeptidyl peptidase inhibitors
|
US7183290B2
(en)
|
2001-06-27 |
2007-02-27 |
Smithkline Beecham Corporation |
Fluoropyrrolidines as dipeptidyl peptidase inhibitors
|
ATE380175T1
(de)
|
2001-06-27 |
2007-12-15 |
Smithkline Beecham Corp |
Pyrrolidine als dipeptidyl peptidase inhibitoren
|
US8377877B2
(en)
|
2001-07-06 |
2013-02-19 |
Kemin Foods, L.C. |
Composition and method for reducing post-prandial blood glucose
|
EP2275117B1
(en)
|
2001-07-31 |
2016-10-26 |
The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services |
GLP-1, exendin-4, peptide analogs and uses thereof
|
GB0121709D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
EP2050460A1
(en)
*
|
2001-09-24 |
2009-04-22 |
Imperial Innovations Limited |
PYY and agonists thereof for modification of feeding behaviour
|
US7238671B2
(en)
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
WO2003033671A2
(en)
|
2001-10-18 |
2003-04-24 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
US6861440B2
(en)
|
2001-10-26 |
2005-03-01 |
Hoffmann-La Roche Inc. |
DPP IV inhibitors
|
US6984645B2
(en)
|
2001-11-16 |
2006-01-10 |
Bristol-Myers Squibb Company |
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
|
JP4771661B2
(ja)
|
2001-11-26 |
2011-09-14 |
トラスティーズ オブ タフツ カレッジ |
Post−プロリン開裂酵素の擬ペプチド性阻害剤
|
EP1487471A4
(en)
*
|
2001-11-26 |
2010-03-10 |
Tufts College |
METHOD FOR TREATING AUTOIMMUNE DISEASES AND ASSOCIATED REAGENTS
|
ATE395613T1
(de)
*
|
2001-12-17 |
2008-05-15 |
Koninkl Philips Electronics Nv |
Verfahren der kernspintomographie
|
EP1461069A2
(en)
|
2001-12-29 |
2004-09-29 |
Novo Nordisk A/S |
Combined use of a glp-1 compound and another drug for treating dyslipidemia
|
US8058233B2
(en)
*
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
BR0307665A
(pt)
|
2002-02-13 |
2005-01-04 |
Hoffmann La Roche |
Compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades associadas com dpp iv e utilização dos compostos
|
MXPA04007743A
(es)
|
2002-02-13 |
2004-10-15 |
Hoffmann La Roche |
Nuevos derivados de piridina y quinolina.
|
EP2204181A3
(en)
*
|
2002-04-30 |
2010-09-22 |
Trustees Of Tufts College |
Protease inhibitors
|
US7057046B2
(en)
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
PT1513519E
(pt)
*
|
2002-06-03 |
2009-05-06 |
Novartis Ag |
Uso de cianopirrolidinas substituídas e preparações de combinações que as contêm para tratar hiperlipidemia e doenças associadas
|
JP2004026678A
(ja)
*
|
2002-06-24 |
2004-01-29 |
Microbial Chem Res Found |
2型糖尿病治療剤
|
CA2491466A1
(en)
*
|
2002-07-09 |
2004-01-15 |
Sharlene Adams |
Methods and compositions relating to isoleucine boroproline compounds
|
EP1528931B1
(en)
*
|
2002-08-09 |
2008-05-07 |
Prosidion Ltd. |
Dipeptidyl peptidase iv inhibitors for decreasing the rate of chronic weight gain
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
AU2003264256A1
(en)
*
|
2002-09-04 |
2004-03-29 |
Dsm Ip Assets B.V. |
A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
|
ATE349804T1
(de)
|
2002-09-06 |
2007-01-15 |
Ericsson Telefon Ab L M |
Zusammengesetzter leistungsverstärker
|
AU2003262059A1
(en)
|
2002-09-11 |
2004-04-30 |
Takeda Pharmaceutical Company Limited |
Sustained release preparation
|
RU2005111253A
(ru)
*
|
2002-09-18 |
2005-11-20 |
Сантр Оспиталье Де Л` Юниверсите Де Монреаль (Схюм) (Ca) |
Аналоги ghrh
|
EP1553937B1
(en)
|
2002-10-23 |
2010-06-02 |
Bristol-Myers Squibb Company |
Glycinenitrile-based inhibitors of dipeptidyl peptidase iv
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
US7166575B2
(en)
*
|
2002-12-17 |
2007-01-23 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
|
GB0300571D0
(en)
*
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
TW200504021A
(en)
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
CN1894234A
(zh)
|
2003-03-25 |
2007-01-10 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
US7160449B2
(en)
|
2003-04-28 |
2007-01-09 |
Vanderbilt University |
Proline chiral columns with broad chiral selectivity
|
DE602004026289D1
(de)
|
2003-05-05 |
2010-05-12 |
Probiodrug Ag |
Glutaminylcyclase-hemmer
|
ATE464889T1
(de)
|
2003-05-05 |
2010-05-15 |
Probiodrug Ag |
Medizinische verwendung von hemmern von glutaminyl und glutamatcyclasen
|
NZ572274A
(en)
|
2003-05-05 |
2009-06-26 |
Probiodrug Ag |
Use of effectors of glutaminyl and glutamate cyclases
|
JP2007511467A
(ja)
|
2003-05-14 |
2007-05-10 |
タケダ サン ディエゴ インコーポレイテッド |
ジペプチジルペプチダーゼインヒビター
|
US7459474B2
(en)
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
CN101090901B
(zh)
|
2003-06-20 |
2010-12-15 |
霍夫曼-拉罗奇有限公司 |
作为dpp-iv抑制剂的六氢吡啶并异喹啉类
|
PT1638970E
(pt)
|
2003-06-20 |
2010-12-13 |
Hoffmann La Roche |
Derivados de pirid(2,1-a)isoquinolina como inibidores de dpp-iv
|
SI1648933T1
(sl)
*
|
2003-07-25 |
2010-01-29 |
Conjuchem Biotechnologies Inc |
Dolgo delujoäś inzulinski derivat in metoda zanj
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
KR20060041309A
(ko)
|
2003-08-13 |
2006-05-11 |
다케다 야쿠힌 고교 가부시키가이샤 |
4-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
|
US7169926B1
(en)
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
JP2007505121A
(ja)
|
2003-09-08 |
2007-03-08 |
武田薬品工業株式会社 |
ジペプチジルぺプチダーゼ阻害剤
|
US7371759B2
(en)
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
EA010108B1
(ru)
|
2003-10-15 |
2008-06-30 |
Пробиодруг Аг |
Применение эффекторов глутаминил- и глутаматциклаз
|
EP1680120A2
(en)
|
2003-11-03 |
2006-07-19 |
Probiodrug AG |
Combinations useful for the treatment of neuronal disorders
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
SI1689757T1
(sl)
|
2003-11-12 |
2015-01-30 |
Sino-Med International Alliance, Inc. |
Heterociklične spojine boronske kisline
|
US7576121B2
(en)
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
KR20060109911A
(ko)
|
2003-11-17 |
2006-10-23 |
노파르티스 아게 |
디펩티딜 펩티다제 ⅳ 억제제의 용도
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
ES2332920T3
(es)
|
2004-01-20 |
2010-02-15 |
Novartis Ag |
Proceso y formulacion de compresion directa.
|
US7304086B2
(en)
|
2004-02-05 |
2007-12-04 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
MXPA06009589A
(es)
*
|
2004-02-23 |
2007-03-26 |
Tufts College |
Inhibidores de dipeptidil peptidasa iv par regular el metabolismo de glucosa.
|
AU2011203039B2
(en)
*
|
2004-02-23 |
2013-02-21 |
Trustees Of Tufts College |
Inhibitors of dipeptidylpeptidase IV for regulating glucose metabolism
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
AU2004318013B8
(en)
|
2004-03-15 |
2011-10-06 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
WO2005118555A1
(en)
|
2004-06-04 |
2005-12-15 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
RU2007101314A
(ru)
*
|
2004-06-15 |
2008-07-20 |
Вандербилт Юниверсити (Us) |
Новые хиральные колонки с широкой хиральной селективностью
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US7145040B2
(en)
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
EP1778220A1
(en)
|
2004-07-12 |
2007-05-02 |
Phenomix Corporation |
Constrained cyano compounds
|
WO2006019965A2
(en)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
ATE553077T1
(de)
*
|
2004-07-23 |
2012-04-15 |
Nuada Llc |
Peptidaseinhibitoren
|
US20060063719A1
(en)
*
|
2004-09-21 |
2006-03-23 |
Point Therapeutics, Inc. |
Methods for treating diabetes
|
US20060094693A1
(en)
*
|
2004-09-21 |
2006-05-04 |
Point Therapeutics, Inc. |
Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
|
AR051446A1
(es)
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
US20060263453A1
(en)
*
|
2004-11-01 |
2006-11-23 |
Thomas Smith |
Methods and compositions for modulating glutamate dehydrogenase
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
US7411093B2
(en)
|
2004-12-20 |
2008-08-12 |
Hoffman-La Roche Inc. |
Aminocycloalkanes as DPP-IV inhibitors
|
RU2396257C2
(ru)
|
2004-12-20 |
2010-08-10 |
Ф.Хоффманн-Ля Рош Аг |
Производные 4-аминопиперидина
|
EP1828192B1
(en)
|
2004-12-21 |
2014-12-03 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7589088B2
(en)
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7635699B2
(en)
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
US7317024B2
(en)
|
2005-01-13 |
2008-01-08 |
Bristol-Myers Squibb Co. |
Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
JP2006232754A
(ja)
*
|
2005-02-25 |
2006-09-07 |
Gi Biopolis:Kk |
消化管粘膜切除後の消化管潰瘍治癒促進用スプレー剤
|
EP2527337A1
(en)
|
2005-04-14 |
2012-11-28 |
Bristol-Myers Squibb Company |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
BRPI0608469A2
(pt)
|
2005-04-22 |
2010-01-05 |
Alantos Pharmaceuticals Holding Inc |
inibidores de dipeptidil peptidase-iv
|
JP5405105B2
(ja)
|
2005-05-04 |
2014-02-05 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン様ペプチド−2(glp−2)アナログ
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7825139B2
(en)
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
GB0511986D0
(en)
*
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
US7888381B2
(en)
|
2005-06-14 |
2011-02-15 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
|
CA2622472C
(en)
|
2005-09-14 |
2013-11-19 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors for treating diabetes
|
US8222411B2
(en)
|
2005-09-16 |
2012-07-17 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
EP2487154B1
(en)
|
2005-10-31 |
2013-10-16 |
Bristol-Myers Squibb Company |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
|
EP1971614A1
(en)
*
|
2005-11-14 |
2008-09-24 |
Probiodrug AG |
Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors
|
JP5165582B2
(ja)
*
|
2005-12-16 |
2013-03-21 |
メルク・シャープ・エンド・ドーム・コーポレイション |
ジペプチジルペプチダーゼ−4インヒビターとメトホルミンとを組み合わせた医薬組成物
|
KR20080077024A
(ko)
*
|
2005-12-19 |
2008-08-20 |
트러스티즈 오브 터프츠 칼리지 |
소프트 단백질분해효소 억제자 및 이의 프로-소프트 폼
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
GB0603252D0
(en)
*
|
2006-02-17 |
2006-03-29 |
Axcess Ltd |
Dissolution aids for oral peptide delivery
|
JP5412273B2
(ja)
*
|
2006-03-21 |
2014-02-12 |
アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー |
ペプチド−ぺプチダーゼ阻害剤及びその使用
|
WO2007112347A1
(en)
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
RS51745B
(en)
|
2006-04-11 |
2011-10-31 |
Arena Pharmaceuticals Inc. |
PROCEDURE FOR USING GPR119 RECEPTORS FOR INDENTIFICATION OF UNITS USEFUL FOR BONE WEIGHT INCREASE
|
BRPI0709984A2
(pt)
|
2006-04-12 |
2011-08-02 |
Probiodrug Ag |
inibidores de enzima
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
BRPI0711558A2
(pt)
|
2006-05-04 |
2011-11-08 |
Boeringer Ingelheim Internat Gmbh |
polimorfos
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
EP2021014A1
(en)
|
2006-05-26 |
2009-02-11 |
Brystol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
US8748419B2
(en)
*
|
2006-06-16 |
2014-06-10 |
Theracos, Inc. |
Treating obesity with muscarinic receptor M1 antagonists
|
UA99259C2
(ru)
*
|
2006-06-16 |
2012-08-10 |
Теракос, Инк. |
Лечение ожирения антагонистами мускаринового рецептора м1
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US7910747B2
(en)
|
2006-07-06 |
2011-03-22 |
Bristol-Myers Squibb Company |
Phosphonate and phosphinate pyrazolylamide glucokinase activators
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
WO2008022015A2
(en)
*
|
2006-08-11 |
2008-02-21 |
Trustees Of Tufts College |
Retro-inverso incretin analogues, and methods of use thereof
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
EP2099767A1
(en)
|
2006-11-01 |
2009-09-16 |
Brystol-Myers Squibb Company |
Modulators of glucocorticoid receptor, ap-1, and/or nf- b activity and use thereof
|
WO2008057862A2
(en)
|
2006-11-01 |
2008-05-15 |
Bristol-Myers Squibb Company |
MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
|
WO2008057855A2
(en)
|
2006-11-01 |
2008-05-15 |
Bristol-Myers Squibb Company |
Heterocyclic compounds as modulators of glucocorticoid receptor, ap-i, and/or np-kappa-b activity
|
WO2008056155A1
(en)
|
2006-11-08 |
2008-05-15 |
Zealand Pharma A/S |
Selective glucagon-like-peptide-2 (glp-2) analogues
|
WO2008055945A1
(en)
|
2006-11-09 |
2008-05-15 |
Probiodrug Ag |
3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
|
ITMI20062254A1
(it)
*
|
2006-11-24 |
2008-05-25 |
Acraf |
Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
ATE554085T1
(de)
|
2006-11-30 |
2012-05-15 |
Probiodrug Ag |
Neue inhibitoren von glutaminylcyclase
|
TWI428346B
(zh)
*
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
AU2007340129B2
(en)
|
2006-12-26 |
2012-02-02 |
Pharmacyclics Llc |
Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
WO2008112939A2
(en)
*
|
2007-03-13 |
2008-09-18 |
Board Of Regents, The University Of Texas System |
Composition and method for making oligo-benzamide compounds
|
AU2008228863A1
(en)
*
|
2007-03-20 |
2008-09-25 |
Trustees Of Tufts College |
Inhibitors of fibroblast activation protein, and methods of use thereof
|
TW200904405A
(en)
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Pharmaceutical formulations containing an SGLT2 inhibitor
|
EP2865670B1
(en)
|
2007-04-18 |
2017-01-11 |
Probiodrug AG |
Thiourea derivatives as glutaminyl cyclase inhibitors
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
WO2008151257A2
(en)
|
2007-06-04 |
2008-12-11 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
CA2694620C
(en)
|
2007-07-19 |
2016-05-31 |
Takeda Pharmaceutical Company Limited |
Solid preparation comprising alogliptin and metformin hydrochloride
|
EP2173717B9
(en)
|
2007-07-27 |
2013-06-26 |
Bristol-Myers Squibb Company |
Novel glucokinase activators and methods of using same
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
CL2008002427A1
(es)
*
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
|
CA2699260A1
(en)
*
|
2007-09-11 |
2009-04-09 |
Mondobiotech Laboratories Ag |
Use of a peptide as a therapeutic agent
|
US20090076013A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched sitagliptin
|
KR20100061692A
(ko)
*
|
2007-09-21 |
2010-06-08 |
사노피-아벤티스 |
(카복실알킬렌-페닐)-페닐-옥살아미드, 이의 제조 방법 및 의약으로서의 이의 용도
|
EP2203448B1
(de)
*
|
2007-09-21 |
2011-06-22 |
Sanofi-Aventis |
Phenothiazin-derivate mit doppelbindung, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
|
US8598314B2
(en)
|
2007-09-27 |
2013-12-03 |
Amylin Pharmaceuticals, Llc |
Peptide-peptidase-inhibitor conjugates and methods of making and using same
|
ES2448839T3
(es)
|
2007-11-01 |
2014-03-17 |
Bristol-Myers Squibb Company |
Compuestos no esteroideos útiles como moderadores de la actividad del receptor de glucocorticoides AP-1 y/o NF-kappa b y uso de los mismos
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
EP2146210A1
(en)
|
2008-04-07 |
2010-01-20 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
|
AU2009256157B2
(en)
|
2008-06-04 |
2014-12-18 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
WO2009158380A1
(en)
|
2008-06-24 |
2009-12-30 |
Bristol-Myers Squibb Company |
Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof
|
EP2321341B1
(en)
|
2008-07-16 |
2017-02-22 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
ES2614427T3
(es)
|
2008-11-07 |
2017-05-31 |
The General Hospital Corporation |
Fragmentos C-terminales de péptido glucagonoide 1 (GLP-1)
|
WO2010062861A2
(en)
|
2008-11-26 |
2010-06-03 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of obesity and diabetes
|
CN102316889B
(zh)
|
2008-11-26 |
2014-11-26 |
萨蒂奥根制药公司 |
组合物及使用方法
|
DE102008062136B4
(de)
|
2008-12-16 |
2012-05-03 |
Kamamed Ug |
Pharmazeutische Zusammensetzung auf Basis von Peptid aus Kamelmilch
|
AP2011005794A0
(en)
|
2009-02-13 |
2011-08-31 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a furtherantidiabetic agent and uses thereof.
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
EP2475428B1
(en)
|
2009-09-11 |
2015-07-01 |
Probiodrug AG |
Heterocylcic derivatives as inhibitors of glutaminyl cyclase
|
JP5798123B2
(ja)
|
2009-11-13 |
2015-10-21 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
低質量のメトホルミン製剤
|
EP2498759B1
(en)
|
2009-11-13 |
2018-08-01 |
AstraZeneca AB |
Immediate release tablet formulations
|
WO2011060256A2
(en)
|
2009-11-13 |
2011-05-19 |
Bristol-Myers Squibb Company |
Bilayer tablet formulations
|
MX364651B
(es)
|
2009-11-27 |
2019-05-03 |
Boehringer Ingelheim Int Gmbh Star |
Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente.
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
ES2586231T3
(es)
|
2010-03-03 |
2016-10-13 |
Probiodrug Ag |
Inhibidores de glutaminil ciclasa
|
CN102791704B
(zh)
|
2010-03-10 |
2015-11-25 |
前体生物药物股份公司 |
谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂
|
WO2011127051A1
(en)
|
2010-04-06 |
2011-10-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
ES2559209T3
(es)
|
2010-04-14 |
2016-02-11 |
Bristol-Myers Squibb Company |
Nuevos activadores de la glucocinasa y métodos de uso de los mismos
|
EP2560953B1
(en)
|
2010-04-21 |
2016-01-06 |
Probiodrug AG |
Inhibitors of glutaminyl cyclase
|
EP2566469B1
(en)
|
2010-05-05 |
2022-12-21 |
Boehringer Ingelheim International GmbH |
Combination therapy
|
EP2575821B1
(en)
|
2010-05-26 |
2015-08-12 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
|
WO2011157827A1
(de)
|
2010-06-18 |
2011-12-22 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
WO2011163231A2
(en)
|
2010-06-21 |
2011-12-29 |
Theracos, Inc. |
Combination therapy for the treatment of diabetes
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
EP2585101A1
(en)
|
2010-06-24 |
2013-05-01 |
Boehringer Ingelheim International GmbH |
Diabetes therapy
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
KR20130137624A
(ko)
|
2010-09-03 |
2013-12-17 |
브리스톨-마이어스 스큅 컴퍼니 |
수용성 항산화제를 사용한 약물 제제
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US10894787B2
(en)
|
2010-09-22 |
2021-01-19 |
Arena Pharmaceuticals, Inc. |
Modulators of the GPR119 receptor and the treatment of disorders related thereto
|
US9040481B2
(en)
|
2010-11-02 |
2015-05-26 |
The General Hospital Corporation |
Methods for treating steatotic disease
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
US11974971B2
(en)
|
2011-01-07 |
2024-05-07 |
Anji Pharmaceuticals Inc. |
Compositions and methods for treating metabolic disorders
|
US9480663B2
(en)
|
2011-01-07 |
2016-11-01 |
Elcelyx Therapeutics, Inc. |
Biguanide compositions and methods of treating metabolic disorders
|
US9572784B2
(en)
|
2011-01-07 |
2017-02-21 |
Elcelyx Therapeutics, Inc. |
Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
|
US11759441B2
(en)
|
2011-01-07 |
2023-09-19 |
Anji Pharmaceuticals Inc. |
Biguanide compositions and methods of treating metabolic disorders
|
US9211263B2
(en)
|
2012-01-06 |
2015-12-15 |
Elcelyx Therapeutics, Inc. |
Compositions and methods of treating metabolic disorders
|
EP3763419A1
(en)
|
2011-01-07 |
2021-01-13 |
Anji Pharma (US) LLC |
Chemosensory receptor ligand-based therapies
|
US8796338B2
(en)
|
2011-01-07 |
2014-08-05 |
Elcelyx Therapeutics, Inc |
Biguanide compositions and methods of treating metabolic disorders
|
US20140079778A1
(en)
|
2011-02-01 |
2014-03-20 |
Astrazeneca Uk Limited |
Pharmaceutical Formulations Including An Amine Compound
|
AR085689A1
(es)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
|
US8530670B2
(en)
|
2011-03-16 |
2013-09-10 |
Probiodrug Ag |
Inhibitors
|
WO2012135570A1
(en)
|
2011-04-01 |
2012-10-04 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012145361A1
(en)
|
2011-04-19 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012145603A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
US20140051714A1
(en)
|
2011-04-22 |
2014-02-20 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2013006526A2
(en)
|
2011-07-05 |
2013-01-10 |
Merck Sharp & Dohme Corp. |
Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
|
WO2013006692A2
(en)
|
2011-07-06 |
2013-01-10 |
The General Hospital Corporation |
Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
|
MX366629B
(es)
|
2011-07-15 |
2019-07-17 |
Boehringer Ingelheim Int |
Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
|
PL2753334T3
(pl)
|
2011-08-30 |
2022-12-12 |
Trustees Of Tufts College |
Aktywowane przez fap inhibitory proteasomu do leczenia guzów litych
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
CA2853285C
(en)
|
2011-10-28 |
2020-05-05 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
|
ES2832773T3
(es)
|
2012-01-06 |
2021-06-11 |
Anji Pharma Us Llc |
Composiciones de biguanida y métodos de tratamiento de trastornos metabólicos
|
EA033067B1
(ru)
|
2012-01-06 |
2019-08-30 |
Элселикс Терапьютикс, Инк. |
Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
CA2872315A1
(en)
|
2012-05-03 |
2013-11-07 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (glp-2) analogues
|
EP3685839A1
(en)
|
2012-05-14 |
2020-07-29 |
Boehringer Ingelheim International GmbH |
Linagliptin for use in the treatment of albuminuria and kidney related diseases
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
IN2015DN03795A
(ja)
|
2012-10-24 |
2015-10-02 |
Inserm Inst Nat De La Santé Et De La Rech Médicale |
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
DK3489226T3
(da)
|
2012-11-20 |
2021-04-26 |
Lexicon Pharmaceuticals Inc |
Hæmmere for natriumglucose-cotransporter 1
|
WO2014102715A1
(en)
|
2012-12-24 |
2014-07-03 |
Ranbaxy Laboratories Limited |
Pharmaceutical compositions comprising a biguanide and a low dose antidiabetic agent
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
WO2014151206A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
WO2014184742A1
(en)
|
2013-05-13 |
2014-11-20 |
Ranbaxy Laboratories Limited |
Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
|
WO2014197720A2
(en)
|
2013-06-05 |
2014-12-11 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
WO2015027021A1
(en)
|
2013-08-22 |
2015-02-26 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
US9902751B2
(en)
|
2013-12-30 |
2018-02-27 |
Mylan Laboratories Limited |
Process for the preparation of empagliflozin
|
FR3017536B1
(fr)
*
|
2014-02-18 |
2017-05-26 |
Univ La Rochelle |
Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
|
EP3110449B1
(en)
|
2014-02-28 |
2023-06-28 |
Boehringer Ingelheim International GmbH |
Medical use of a dpp-4 inhibitor
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
KR20220070057A
(ko)
|
2015-03-09 |
2022-05-27 |
인테크린 테라퓨틱스, 아이엔씨. |
비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
|
EP3273981B1
(en)
|
2015-03-24 |
2020-04-29 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Method and pharmaceutical composition for use in the treatment of diabetes
|
US10674746B2
(en)
|
2015-10-27 |
2020-06-09 |
Cytozyme Animal Nutrition, Inc. |
Animal nutrition compositions and related methods
|
BR112018007434A2
(pt)
|
2015-10-27 |
2018-10-23 |
Cytozyme Animal Nutrition Inc |
composições para nutrição animal, usos e métodos relacionados
|
US11142546B2
(en)
|
2016-04-04 |
2021-10-12 |
Research Triangle Institute |
Neuropeptide S receptor (NPSR) agonists
|
WO2017211979A1
(en)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinations of linagliptin and metformin
|
MX2019006486A
(es)
|
2016-12-09 |
2019-08-01 |
Zealand Pharma As |
Agonistas duales acilados de glp-1/glp-2.
|
WO2018162722A1
(en)
|
2017-03-09 |
2018-09-13 |
Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke |
Dpp-4 inhibitors for use in treating bone fractures
|
AU2018249822A1
(en)
|
2017-04-03 |
2019-10-31 |
Coherus Biosciences Inc. |
PPArgamma agonist for treatment of progressive supranuclear palsy
|
PL3461819T3
(pl)
|
2017-09-29 |
2020-11-30 |
Probiodrug Ag |
Inhibitory cyklazy glutaminylowej
|
JP2021530517A
(ja)
|
2018-07-19 |
2021-11-11 |
アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag |
ダパグリフロジンを使用してHFpEFを処置する方法、及びダパグリフロジンを含む組成物
|
SG11202102498UA
(en)
|
2018-09-26 |
2021-04-29 |
Lexicon Pharmaceuticals Inc |
Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
|
TW202220672A
(zh)
|
2020-07-27 |
2022-06-01 |
瑞典商阿斯特捷利康公司 |
用達格列淨治療慢性腎臟病之方法
|
KR20220151434A
(ko)
*
|
2021-05-06 |
2022-11-15 |
엘지디스플레이 주식회사 |
범프를 포함하는 표시장치
|
WO2023144722A1
(en)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
|